Institutions / Aisling Capital Management LP
Aisling Capital Management LP
CIK 1766721 · Institution · as of Dec 31, 2025
Portfolio value
$478.92M
Positions
13
As of
Dec 31, 2025
Top holdings
Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| BridgeBio Pharma, Inc. | $389.30M | 81.3% |
| Syndax Pharmaceuticals Inc | $27.67M | 5.8% |
| Monte Rosa Therapeutics, Inc. | $23.09M | 4.8% |
| Bicara Therapeutics Inc. | $9.57M | 2.0% |
| COMPASS Pathways plcCMPS | $8.27M | 1.7% |
| BridgeBio Oncology Therapeutics, Inc.BBOT | $7.07M | 1.5% |
| CalciMedica, Inc.CALC | $3.43M | 0.7% |
| Scholar Rock Holding Corp | $3.39M | 0.7% |
| Biomea Fusion, Inc.BMEA | $2.54M | 0.5% |
| Urogen Pharma Ltd. (URGN) | $2.53M | 0.5% |
| Aclaris Therapeutics, Inc. | $1.31M | 0.3% |
| Marker Therapeutics, Inc. (MRKR) | $484.8K | 0.1% |
| OnKure Therapeutics, Inc. | $257.0K | 0.1% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.